Aberdeen Asset Management says Pfizer could do better on price

Reuters Staff

1 Min Read

LONDON, May 19 (Reuters) - Aberdeen Asset Management, a leading investor in drugmaker AstraZeneca, said on Monday that U.S. group Pfizer had room to improve its 55-pounds-per-share offer for its British rival.

“The price is finely balanced,” Chief Investment Officer Anne Richards told BBC radio. “I think it’s a good price that’s on the table at the moment but probably they could do better than that.”